An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
- Conditions
- Juvenile Idiopathic Arthritis
- Registration Number
- NCT01357668
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 800
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate of serious infections 10 years Incidence rate of malignancies 10 years Incidence rate of autoimmune disorders 10 years
- Secondary Outcome Measures
Name Time Method Number of serious adverse events 10 years Number of targeted infections (Epstein-Barr virus, cytomegalovirus, papilloma virus, herpes zoster, tuberculosis and opportunistic infections) 10 years
Trial Locations
- Locations (59)
Local Institution - 0060
🇺🇸Little Rock, Arkansas, United States
Local Institution - 0001
🇺🇸Princeton, New Jersey, United States
Local Institution - 0059
🇺🇸Cincinnati, Ohio, United States
Local Institution - 0025
🇦🇹Bregenz, Austria
Local Institution - 0002
🇦🇹Innsbruck, Austria
Local Institution - 0032
🇦🇹Vienna, Austria
Local Institution - 0010
🇧🇷Botucatu, São Paulo, Brazil
Local Institution - 0026
🇧🇷Campinas, São Paulo, Brazil
Local Institution - 0028
🇧🇷São Paulo, São Paulo, Brazil
Local Institution - 0027
🇧🇷Rio de Janeiro, Brazil
Scroll for more (49 remaining)Local Institution - 0060🇺🇸Little Rock, Arkansas, United States